Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.
Abstract
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide. These agents have been shown to reduce A1C (by ∼0.8–1.6%), body weight (by ∼1–3 kg), blood pressure, and lipids. GLP-1 receptor agonists are associated with a low risk of hypoglycemia, and the most common adverse effects are gastrointestinal. Proper patient selection and education can assist in achieving positive treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GI AE profile of semaglutide 2.4 mg in the STEP trials is consistent with previous observations with lower semaglutide doses and the established AE profile of GLP‐1RAs. 14 , 28 , 29”
From Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As higher incidences of GI AEs tend to be experienced with higher doses of GLP‐1RAs, gradual dose escalation and dose adjustment may help mitigate the impact of GI AEs in clinical practice. 29 , 30”
In the citing paper
“GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements to β-cell function and peripheral insulin sensitivity ( Zander et al., 2002 ; Hinnen, 2017 ).”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Hinnen, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similar positive cardiovascular results were reported recently for semaglutide, an investigational GLP-1 receptor agonist administered QW (33).”
ResultMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Two incretin hormones have been identified: glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) (4).”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“O R G The incretin system has become an important target in the treatment of type 2 diabetes in recent years (1).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is reduced in people with type 2 diabetes (6).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Research works printed but not linked: 2
- Johnson, 2014, Integrated phase 3 immunogenicity results for albiglutide, Diabetes, 63, A427
- Milicevic, 2015, Low incidence of anti-drug antibody in type 2 diabetes patients treated with once-weekly dulaglutide, Diabetes, 64, A292
Cited by
Items 301–400 of 410
Advanced Peptide Modifications for Superior Therapeutics
Bhadra, J., De, N., Momin, M. S. A., Sannigrahi, A., & Bhunia, D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00826 · Cited by 2
Novel Treatments and the Future of DKD: What Is on the Horizon?
Wu, H., & Batuman, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_28 · Cited by 2
Abdi, A., Soleymanpour, A., & Shafaatian, B. (2022) · ChemistrySelect · doi:10.1002/slct.202202132 · Cited by 2
Larsen, R. G., van de Cruijs, C., Eggertsen, C. N., Handberg, A., Warner, T. C., Frøkjær, J. B., Vestergaard, E. T., & Hagstrøm, S. (2022) · Acta Physiologica · doi:10.1111/apha.13875 · Cited by 2
San, K., Fogel, J., & Khazron, D. (2023) · Southern Medical Journal · doi:10.14423/smj.0000000000001511 · Cited by 2
“resulting in an overall reduction of HbA1c.(14,15) We did not, however, see statistically significant differences when we compared follow-up HbA1c between the GFR groups.”
ResultYao, J., Zhang, M., Zhang, X., & Zhang, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01369-6 · Cited by 2
“GLP-1 receptor agonists target a range of underlying pathogenic processes in addition to stimulating insulin secretion from b cells [4].”
BackgroundKurniati, N. F., & Fathadina, A. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e96975 · Cited by 3
A minimal mathematical model to study insulin synthesis and secretion process
Paul, A., Kundu, J., & Chatterjee, S. (2023) · Applied Mathematical Modelling · doi:10.1016/j.apm.2023.06.012 · Cited by 2
Naz, F., Qadir, R., Baammi, S., Ali, A., & Rehman, M. U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15336-5.00012-9 · Cited by 2
Beyond pounds: What else could be lost?
Idrees, T., & Umpierrez, G. E. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108649 · Cited by 2
Chakravarti, H. N., Kesavadev, J., KOVIL, R. R., Sanyal, D., Das, S., Roy, N., Kumar, D., Deb, B., Chaudhuri, S. R., & Aneja, P. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_11_24 · Cited by 2
Xia, L., Li, H., Huang, S., & Shen, L. (2024) · Biomedical Reports · doi:10.3892/br.2024.1913 · Cited by 2
tPA ‐ GFP is a reliable probe for detecting compound exocytosis in human pancreatic β‐cells
Makam, A. A., Sharma, S., Nagle, P., Sundaram, N. M., Prasad, V. M., & Gandasi, N. R. (2024) · FASEB BioAdvances · doi:10.1096/fba.2024-00131 · Cited by 2
Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease
Yang, H., & Park, C. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.2.88 · Cited by 2
“kr 91 는 exenatide, liraglutide, exenatide extended-release, albiglutide와 lixisenatide가 있다[33].”
GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists
Gillenwater, B. A., Wakefield, A. N., Triboletti, J. S., Gonzalvo, J. D., & Meredith, A. H. (2019) · AADE in Practice · doi:10.1177/2325160319861453 · Cited by 2
“Many of the GLP-1 agonist manufacturers offer programs to reduce copays for non–government funded insurance plans.(37) Diabetes educators should become familiar with the preferred GLP-1 agonists for common insurance plans in their geographic area to reduce barriers when initiating therapy.”
BackgroundGorvin, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00020-7 · Cited by 2
Metformin in the Era of New Antidiabetics
Al-Mahdi, E. A. R., Barrios, V., & Zamorano, J. L. (2021) · Future Cardiology · doi:10.2217/fca-2020-0195 · Cited by 2
Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?
Azeez, T. A., Folorunso, S. A., Eguzozie, C., & Adegboyega, A. A. (2021) · Forum of Clinical Oncology · doi:10.2478/fco-2021-0014 · Cited by 2
Elder, M. J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211049032 · Cited by 2
“GLP-1 is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying, making it a target of interest in treating diabetes.(4) There are currently 7 GLP-1 RA that are FDA approved for the treatment of diabetes.”
BackgroundInfluentialPharmacotherapy of Type 2 Diabetes Mellitus
Jha, P. K., Shukla, H., Makwana, A., & Kakkad, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002309 · Cited by 4
Type 2 diabetes mellitus: Novel targets and multitarget-directed phytotherapy
Chhipa, A. S., Verma, S., & Patel, S. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95719-9.00008-2 · Cited by 1
Srour, L., Ismail, J., Njeim, R., & Eid, A. A. (2024) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-62131-4_8 · Cited by 2
Panchal, N., & Vaghela, V. M. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3339 · Cited by 2
“82,83”
Introduction to diabetes mellitus
Nidhar, M., Sura, S., Kumar, V., & Tewari, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00007-5 · Cited by 1
Wong, S., Fabiano, N., Zhou, C., Luu, B., Shorr, R., Slassi, S., Solmi, M., Husain, M. I., & Mak, M. S. B. (2025) · Psychiatry International · doi:10.3390/psychiatryint6030111 · Cited by 1
“Additionally, GLP-1RAs (with the exception of exenatide and lixisenatide) are contraindicated in people with multiple endocrine neoplasia syndrome type 2, or a personal or family history of medullary thyroid carcinoma [45].”
Predictors of Post‐Bariatric Surgery Hypoglycemia: A Multicenter Retrospective Cohort Study
Bahardoust, M., Ranjbarpazuki, A., Shamohammadi, M., Mousavi, A., Yarahmadi, D., Haghmoradi, M., Goodarzy, B., Garavand, A. A., & Tizmaghz, A. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70123 · Cited by 2
Glucagon-like Peptide-1 Agonists and Exercise for Weight Reduction: A Review of Current Evidence
Owaidat, J. F., Zuaiter, S., Daseh, A. I., Nemrawi, F. A. A., Abu‐Jeyyab, M., & Al-Jafari, M. (2025) · JAP Academy Journal · doi:10.4103/japaj.japaj_5_24 · Cited by 1
A Shift from Diabetic Clinical Therapy to Aesthetic Use: The Ozempic Phenomenon
Sibarani, N. T., Simanjuntak, A. A., Simanjuntak, D. M. P., Tuba, S., Priyono, A., Sumaryono, B., & Sari, E. P. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.142019 · Cited by 1
Trykall, C. C., Hill, S. B., James, A. M., Bagnola, A. J., Wyne, K. L., Handley, D., & Brower, K. I. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.02.002 · Cited by 3
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Rational Design and Evaluation of Novel TGR5 Agonists for Diabetes
Bhimanwar, R. S., Detwiler, Z., Zhu, J. G., Saghafi, S. T., Winder, C., Davis, D. B., Mittal, A., Sharma, V., Harris, D. A., & Chaudhari, S. N. (2026) · Molecules · doi:10.3390/molecules31071093 · Cited by 1
Zadeh, A. T., Chiapparelli, E. A., Amoroso, K., Guven, A. E., Zhu, J., Köhli, P., Verna, B., Mielke, A. M., Shue, J., Burkhard, M. D., et al. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261446300 · Cited by 2
Wang, K., Chen, Y., Strizek, A., Boye, K. S., Gu, L., Liu, Y., & Qu, S. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.08.003 · Cited by 1
Imarhia, F. I., & Malveaux, J. (2020) · Federal Practitioner · doi:10.12788/fp.0057 · Cited by 1
Assunção, I. L., Gonzalez, G. M. M., da Silva, V. M., de Carvalho, C. S. V., Machado, A. G. M., dos Santos, V. M., Pascoal, G. D. A., Forest, G. O., de Sousa, J. C. F., Fonseca, I. A. R., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i16.23517 · Cited by 1
“Desta forma o medicamento visa aumentar a produção de insulina, para compensar a resistência periférica ao hormônio (Drucker, 2018; Hinnen, 2017).”
BackgroundWinkler, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.8 · Cited by 2
Glucagon-like Peptide-1 (GLP-1) Agonists: A Review
Lenkapothula, N., & Srivani, B. (2021) · doi:10.51521/ijmhr.2021.1104 · Cited by 1
Nedyalkova, M., Robeva, R. N., Romanova, J., Yovcheva, K., Lattuada, M., & Simeonov, V. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2330714 · Cited by 1
“GLP-1 is an intestinal hormone that could increase post-prandial glucose-dependent insulin secretion, thus regulating glucose homeostasis (Drucker & Nauck, 2006; Hinnen, 2017).”
Precision medicine: recent advances, current challenges and future perspectives
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5042-7 · Cited by 1
Zhang, K., Zhao, A., Wang, Z., Ye, K., Xu, Z., Gong, X., & Zhu, G. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01449-1 · Cited by 1
“…(e.g. exenatide), which require twice-daily subcutaneous injections, to longer-acting formulations (e.g. liraglutide), which require a once-daily subcutaneous injection, and ultra-long-acting formulations (e.g. dulaglu-tide or semaglutide), which require a once-weekly subcutaneous injection [7, 8].”
Advances in the Design of Novel Antidiabetic Agents Using In-silico Approaches
Jadhav, S., Yeram, P. B., Alavala, R. R., & Vora, A. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_21 · Cited by 1
Diabetes mellitus: An overview
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00007-x · Cited by 1
MIR192 upregulates GLP-1 receptor and rescues statin-induced impairment of insulin secretion
Kuang, Y., Locatelli, C. A. A., Zhang, Y., Qin, Y., Theusch, E., Munoz-Howell, A., Sanchez, G., Lu, M., Nguyen, M.-A., Yalamanchili, T., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03353-3 · Cited by 1
Antidiabetic Phytochemicals and Their Applications in Modern Medicine
Krishna, M. S., & Arun, K. B. (2020) · Springer eBooks · doi:10.1007/978-981-15-1761-7_11 · Cited by 1
Novel metabolic risk markers in obesity and type two Diabetes mellitus
Alramah, T. (2020) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.81327 · Cited by 4
Handley, D., Almansoori, S., Sato, M. S., Amin, H. A., Alsters, S., Chahal, H., Purkayastha, S., Murphy, K. G., van Haelst, M. M., le Roux, C. W., et al. (2023) · medRxiv · doi:10.1101/2023.05.22.23290347 · Cited by 1
“GLP1 agonists are well-established treatments for type 2 diabetes (T2D) and obesity (Kelly et al., 2013; Hinnen, 2017; Webb et al., 2017; Patel and Smith, 2021; Wilding et al.,2021).”
BackgroundKerry, R. G., Naik, H., Mahapatra, S. R., Nayak, S., Behera, A., Pattanaik, K. P., Ranjan, S., Misra, N., Rout, J. R., Das, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5022136/v1 · Cited by 1
Sandoval Vásquez, R. A., Carvajal, D. C. S., & Rolleri, M. A. V. (2018) · Repositorio Institucional E-DocUR (Universidad Del Rosario) · doi:10.48713/10336_18879 · Cited by 1
Acute, chronic, prevention, and recovery stages
Al-Shura, A. N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817580-4.00009-3
Al-Shura, A. N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817570-5.00009-8
Role of Glucagon-Like Peptide-1 Analogues on Obesity and Type-II Diabetes Mellitus: A Review
Maheswary, L. A., Navis, S., Anusree, S. S., & R, P. G. R. D. P. G. (2020) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2020.v64i02.017
“Intravenous administration of exogenous GLP-1 to patients with T-IIDM was shown to reduce plasma glucose concentrations to the normal fasting range, even in patients who had an inadequate response to oral anti-hyperglycemic drugs.(23)”
Insulin: Roles and Functions in Biochemistry and U.S. Healthcare
Brinkley, M. R. (2021) · Western CEDAR (Western Washington University)
Effects of low intensity pulsed ultrasound stimulation on metabolic lipolysis of adipocytesPreprint
Kim, S., & Yoon, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.29.486238
“Chemical stimulations increase the activation of all three layers of ATGL, HSL, and MGL at both RNA and protein levels during lipolysis, which may cause side effects [8].”
BackgroundImpact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater
Tran, V., Tran, H., Demirel, S., & Thompson‐Moore, N. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221087933
“6% (9–18 mmol/mol) and 1–3 kilograms.(1) From the findings of this retrospective cohort study, the mean change in HbA1c and weight from baseline to the first HbA1c check for patients with HbA1c ≥ 9% (75 mmol/mol) were 2.”
BackgroundKiss, K. A., Borbáth, L., Hajós, P., Kis, J. T., & Winkler, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.23
“Ennél lényegesebb, hogy az alkalmazásával kapcsolatos gastrointestinalis mellékhatásként a leírások többségében a nausea, a vomitus és a hasi diszkomfortérzés (hasi distensio, flatulentia) szerepel hangsúlyosan.(3,8,9,17) A liraglutid törzskönyvi előirata ritka lehetőségként felsorolja ugyan bélpasszázszavar előfordul…”
Novel drugs in pharmacotherapy of obesity
Hartinger, J. M. (2021) · Praktické lékárenství · doi:10.36290/lek.2021.015
“Jako neinzulinové antidiabetikum liraglutid přirozeně přispívá ke snížení glykovaného hemoglobinu a glykemie na lačno (45) a právě v terapii obézních diabetiků jsou GLP-1 analoga výhodná, neboť nezpůsobují hypoglykemie spojené s pocitem hladu (naopak vyvolávají pocit plnosti žaludku, vzácně mohou vyvolat gastroparézu)…”
InfluentialThe evidence behind early aggressive multi-drug treatment in type 2 diabetes
Cersósimo, E., Solis‐Herrera, C., & Triplitt, C. L. (2021) · Trends in Diabetes and Metabolism · doi:10.15761/tdm.1000121 · Cited by 1
Sewell, J., & Johnson, R. (2022) · Physician Assistant Clinics · doi:10.1016/j.cpha.2022.10.007
Kahraman, Ç., & Çankaya, İ. İ. T. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123043123010004
Diabetes mellitus type-2: The panoramic view of potential therapeutic targets
Anuradha, A., Mittal, A., & Sharma, S. (2023) · AIP conference proceedings · doi:10.1063/5.0169009
Jamali, A. N., & Soni, R. (2023) · International Journal of Pharmaceutical Investigation · doi:10.5530/ijpi.13.4.097 · Cited by 1
Régulation et fonctions du facteur de transcription ChREBP dans l'épithélium intestinal
Charifi, W. (2021) · theses.fr (ABES) · doi:10.70675/89543c3fz31abz4d56zaa7bz77c2c07ffd69
Rusminingsih, E., Susanto, H., Afifah, D. N., Wibowo, J., & Anas, Y. (2024) · Jurnal Kebidanan dan Keperawatan Aisyiyah · doi:10.31101/jkk.3553
“(Hinnen, 2017).”
Interpretation of cardiovascular outcome trials results of new antidiabetic agents
Koh, G., & CHIN, H. (2024) · Journal of Medicine and Life Science · doi:10.22730/jmls.2024.21.3.62
Current Approach of Diabetes Mellitus in Obese Patients
Karaburgu, S. (2023) · doi:10.69860/nobel.9786053359111.8
Guidance on Preoperative Management of Hand Surgery Patients Taking GLP-1 Receptor Agonists
Kisiel, S. C., Hiredesai, A. N., Dhupati, P., & Noland, S. S. (2024) · Hand · doi:10.1177/15589447241300712
Low Intensity Pulsed Ultrasound Stimulation to Modulate Fat Cells and T Cell
Turner, S., Amin, M., Bhattacharjee, A., & Yoon, S. (2024) · IEEE Ultrasonics, Ferroelectrics, and Frequency Control Joint Symposium (UFFC-JS) · doi:10.1109/uffc-js60046.2024.10793462
“Chemical stimulations increase the activation of all three layers of ATGL, HSL, and MGL at both RNA and protein levels during lipolysis, which may cause side effects [20].”
J, P., Tummuru, M., & Ramkumar, K. (2025) · Biotechnology progress (Print) · doi:10.1002/btpr.3529
Al-Badri, M. R., Dhaver, S., & Hamdy, O. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70054 · Cited by 1
“Short-acting agents such as exenatide, administered twice daily, showed diminishing effectiveness in controlling overnight and fasting plasma glucose, but sustained its impact on gastric emptying upon long-term use [1, 2].”
Writing Task Force iCARDIO-Alliance (2025) · Global Cardiology · doi:10.4081/cardio.2025.71 · Cited by 1
Miscellaneous drug combinations in diabetes mellitus
Agarwal, S., Devi, M., Mani, D. N., & Gupta, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00005-1
Pharmacological Interventions for Diabetes Management
Hay-Bradford, E. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_4
Cellular Senescence in Amyotrophic Lateral Sclerosis (ALS)
Syed, R. U., Afsar, S., & Pillo, F. D. (2025) · Springer eBooks · doi:10.1007/978-981-96-8873-9_9
Glucagon-Like Peptide-1 Receptor Agonists: An Overview of Perioperative Surgical Considerations
Cammock, H., Bruenderman, E. H., & Marshall, G. R. (2025) · Current Surgery Reports · doi:10.1007/s40137-025-00461-z
“Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from the small intestine following food ingestion [9].”
Zhang, X., Wang, L., Zhao, J., & Zhao, H. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.08.007
Ekakitie, L. I., Olojo, F. O., Idowu, O. T., Owolabi, O. V., Ajiboye, B. O., & Oyinloye, B. E. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07588-9
“Patients with type 2 diabetes can benefit from the use of GLP −1 receptor agonists as monotherapies or as supplements to other antihyperglycemic medications, such as insulin, to reduce their body weight and A1C levels [31].”
Lee, H., Lee, M., Park, Y. K., & Lee, J. (2025) · Journal of the Korean Society of Food Science and Nutrition · doi:10.3746/jkfn.2025.54.9.723
Glucagon-Like Peptide-1: The Role of Calcium in Gut-Glucose Axis
Foamkom, A.-I., Abdelhady, H. G., & Razzaque, M. S. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-04357-3_10 · Cited by 1
Hussein, M., Ahmed, A. I., & Syam, H. S. (2025) · Advances in Animal and Veterinary Sciences · doi:10.17582/journal.aavs/2025/13.s1.56.69
Rakib, M. A., & Kim, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157666 · Cited by 1
Agarwal, A., Patnaik, A., Gupta, E., Jaiswal, B., & Gupta, A. K. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117616
Incretin-based therapies in patients with Type 2 diabetes mellitus and renal impairment
Howse, P. M. (2023) · Memorial University Research Repository (Memorial University) · doi:10.48336/hems-sk50 · Cited by 1
Surface-modified nanoparticles with novel peptides targeting the intestinal neonatal Fc receptor
Teixeira, N. B. D. G. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/thqg-w469 · Cited by 3
Additional file 1 of GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo
Arcones, A. C., Vila‐Bedmar, R., Mirasierra, M., Cruces‐Sande, M., Vallejo, M., Jones, B. J., Tomás, A., Mayor, F., & Murga, C. (2021) · Figshare · doi:10.6084/m9.figshare.14157718
TALLYHO/JngJ as a model for type 2 diabetes-induced bone disease
Emini, L. (2023) · Qucosa (Saxon State and University Library Dresden)
Föchterle, S. (2020) · University Library Linz repository (Johannes Kepler Universitat Linz)
GLP1 acts on the carotid body to modulate glucose homeostasis and cardiorespiratory responses
Pires, D. S. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Notkun sykursýkislyfja á Íslandi á árunum 2008-2017 - Samanburður við Norðurlönd
Magnúsdóttir, A. E. (2020) · Skemman
Farmácia Gândara, Vila Nova de Gaia
Barbosa, P. J. F. (2023) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/pf48-p260
Ramos, L. C. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Pharmacogenetic Insights into Glucagon-Like Peptide-1 Receptor and Its Role in Diabetes Therapy
Davis, C., Taylor, L., & Moore, I. (2023) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/qbaabzn70k
Kumarihami, M., Kekulandara, D. N., Gunathilake, K. D. P. P., & Jeevathayaparan, S. (2025) · Journal of Science of the University of Kelaniya · doi:10.4038/josuk.v18i2.8172
Fonseca, É. P. F. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w
Foundations of Diabetes Technology
Joshi, D. M., Bhatt, H., & Patel, H. K. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813635126010006
Le rôle du récepteur aux LDL et de PCSK9 dans le diabète de type 2
Ramin‐Mangata, S. (2020) · theses.fr (ABES) · doi:10.70675/26622ba5zb0fcz4d30za6e6z5c95a0b5a33d
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Rathore, G., & Singh, R. P. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2675316
Metadata
- Authors
- Hinnen, D.
- Affiliations
- University of Colorado Health (US)
- Corresponding author
- Hinnen, Deborah
- ORCID
- Hinnen, Deborah
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2017-08-01
- Volume
- 30
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC5556578
- OpenAlex
- W2592545469
- Cited by
- 394
- References
- 53
- Citations by year
- 2026: 23 · 2025: 71 · 2024: 59 · 2023: 57 · 2022: 53 · 2021: 59 · 2020: 46 · 2019: 22 · 2018: 3 · 2017: 1
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- AstraZeneca
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, incretin system, exenatide, liraglutide, lixisenatide, exenatide extended-release, albiglutide, dulaglutide, glycemic control, weight loss, hypoglycemia risk, gastrointestinal adverse effects, patient selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.